News | June 05, 2021
Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
The acquisition will strengthen the overall company’s position as leading global CRO services partner
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Subscribe To Our Newsletter & Stay Updated
